FDA Approves Lynparza Combo as First-line Maintenance Therapy for Advanced Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who responded to platinum-based chemotherapy. This indication also includes patients who have advanced fallopian tube or primary peritoneal cancer. HRD-positive tumors — present in one of every two women with advanced ovarian cancer — have mutations in certain genes involved in DNA repair, including the BRCA genes, and/or genomic instability (a high frequency of…

You must be logged in to read/download the full post.